Clinical trials: Takayasu Arteritis

Takayasu Arteritis

A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)

• Terminated
• Age: 15 to 75 years
• Phase 3
• Results posted

The purpose of this study is to evaluate the efficacy of ustekinumab compared to placebo, in combination with oral glucocorticoid (GC) taper regimen, in participants with relapsing Takayasu Arteritis (TAK).

Trial name

NCT04882072

Testing

Ustekinumab, Glucorticoid Taper Regimen

Where

27 sites in Japan

Volunteers

14 people

Sponsor

Janssen Pharmaceutical K.K.